Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Cancer Immunology at the Crossroads: Complementary Therapeutic Modalities

  • Cancer Immunology at the Crossroads: Complementary Therapeutic Modalities | Free Article
    Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed
    Rasha Abu Eid, Ghazaleh Shoja E. Razavi, Mikayel Mkrtichyan, John Janik and Samir N. Khleif
    Cancer Immunol Res May 1 2016 4 (5) 377-382; DOI:10.1158/2326-6066.CIR-16-0048

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
    Jarushka Naidoo, Katja Schindler, Christiane Querfeld, Klaus Busam, Jane Cunningham, David B. Page, Michael A. Postow, Alyona Weinstein, Anna Skripnik Lucas, Kathryn T. Ciccolini, Elizabeth A. Quigley, Alexander M. Lesokhin, Paul K. Paik, Jamie E. Chaft, Neil H. Segal, Sandra P. D'Angelo, Mark A. Dickson, Jedd D. Wolchok and Mario E. Lacouture
    Cancer Immunol Res May 1 2016 4 (5) 383-389; DOI:10.1158/2326-6066.CIR-15-0123

    Bullous pemphigoid is a rare immune-related adverse event after anti–PD-1/PD-L1 immune checkpoint treatment and may be mediated by both T-cell and B-cell responses. Early referral to dermatology for accurate diagnosis and management is recommended.

Research Articles

  • Research Articles
    Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes
    Andres Forero, Yufeng Li, Dongquan Chen, William E. Grizzle, Katherine L. Updike, Natalie D. Merz, Erinn Downs-Kelly, Todd C. Burwell, Christos Vaklavas, Donald J. Buchsbaum, Richard M. Myers, Albert F. LoBuglio and Katherine E. Varley
    Cancer Immunol Res May 1 2016 4 (5) 390-399; DOI:10.1158/2326-6066.CIR-15-0243

    The MHC II pathway is usually turned off in tumor cells. Expression in triple-negative breast tumors was correlated with antitumor responses and reduced relapse risk. MHC II expression may predict good prognosis, and inducing it may have therapeutic benefits.

  • Research Articles
    IFNγ-Dependent Interactions between ICAM-1 and LFA-1 Counteract Prostaglandin E2–Mediated Inhibition of Antitumor CTL Responses
    Fatemah Salem Basingab, Maryam Ahmadi and David John Morgan
    Cancer Immunol Res May 1 2016 4 (5) 400-411; DOI:10.1158/2326-6066.CIR-15-0146

    Robust antitumor CTL responses require adhesion of the killer cell to tumor cells. PGE2 suppresses CTL function, but this could be overcome by the IFNγ-induced upregulation of ICAM-1, which drove CTL generation and limited tumor growth in vivo.

  • Research Articles
    TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination
    Melody S. Hsu, Shaina Sedighim, Tina Wang, Joseph P. Antonios, Richard G. Everson, Alexander M. Tucker, Lin Du, Ryan Emerson, Erik Yusko, Catherine Sanders, Harlan S. Robins, William H. Yong, Tom B. Davidson, Gang Li, Linda M. Liau and Robert M. Prins
    Cancer Immunol Res May 1 2016 4 (5) 412-418; DOI:10.1158/2326-6066.CIR-15-0240

    A clinically translatable platform was developed to track T-cell populations without prior knowledge of their specificity. TCR sequencing data could be used to distinguish patients with glioblastoma who will benefit and are benefitting from immunotherapy.

  • Research Articles
    Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
    Andrew Gabrielson, Yunan Wu, Hongkun Wang, Jiji Jiang, Bhaskar Kallakury, Zoran Gatalica, Sandeep Reddy, David Kleiner, Thomas Fishbein, Lynt Johnson, Eddie Island, Rohit Satoskar, Filip Banovac, Reena Jha, Jaydeep Kachhela, Perry Feng, Tiger Zhang, Anteneh Tesfaye, Petra Prins, Christopher Loffredo, John Marshall, Louis Weiner, Michael Atkins and Aiwu Ruth He
    Cancer Immunol Res May 1 2016 4 (5) 419-430; DOI:10.1158/2326-6066.CIR-15-0110

    Tumor immune infiltration is a prognostic marker for relapse in patients with colorectal cancer. The Immunoscore methodology was extended to patients with hepatocellular carcinoma. The Immunoscore could predict the risk of postsurgical relapse and duration of relapse-free survival.

  • Research Articles
    Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy
    Damiana Antonia Faè, Debora Martorelli, Katy Mastorci, Elena Muraro, Jessica Dal Col, Giovanni Franchin, Luigi Barzan, Elisa Comaro, Emanuela Vaccher, Antonio Rosato and Riccardo Dolcetti
    Cancer Immunol Res May 1 2016 4 (5) 431-440; DOI:10.1158/2326-6066.CIR-15-0108

    Adoptive T-cell immunotherapy induces some responses in patients with nasopharyngeal carcinoma, but specificities are limited. A simple protocol is described that generates highly effective specific T cells, which could make adoptive immunotherapy more widely applicable.

  • Research Articles
    Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice
    Andrea Sobo-Vujanovic, Lazar Vujanovic, Albert B. DeLeo, Fernando Concha-Benavente, Robert L. Ferris, Yan Lin and Nikola L. Vujanovic
    Cancer Immunol Res May 1 2016 4 (5) 441-451; DOI:10.1158/2326-6066.CIR-15-0104

    The role of soluble TNF in tumorigenesis, distinct from transmembrane TNF, was delineated. Soluble TNF promoted chemically induced carcinogenesis and mediated the expansion of myeloid-derived suppressor cells. This pathway could serve as a potential target for cancer prevention and therapy.

  • Research Articles
    Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti–PD-L1 Immune Checkpoint Inhibitor
    Amanda J. Vandeveer, Jonathan K. Fallon, Robert Tighe, Helen Sabzevari, Jeffrey Schlom and John W. Greiner
    Cancer Immunol Res May 1 2016 4 (5) 452-462; DOI:10.1158/2326-6066.CIR-15-0176

    In an orthotopic model of non-muscle invasive bladder cancer, in which BCG had minimal activity, systemic administration of the anti–PD-L1 checkpoint inhibitor avelumab demonstrated durable antitumor responses and long-term survival mediated by CD4 and CD8 T cells.

  • Research Articles
    Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma
    Hirokazu Matsushita, Yusuke Sato, Takahiro Karasaki, Tohru Nakagawa, Haruki Kume, Seishi Ogawa, Yukio Homma and Kazuhiro Kakimi
    Cancer Immunol Res May 1 2016 4 (5) 463-471; DOI:10.1158/2326-6066.CIR-15-0225

    In ccRCC the abundant neoepitopes associated with more effective antitumor immune responses were counterbalanced by a strongly immunosuppressive microenvironment. Therefore, combining blockade of immunosuppressive molecular pathways with immunotherapies targeting neoantigens may achieve synergistic antitumor activity.

Correction

  • Correction
    Correction: Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer
    Cancer Immunol Res May 1 2016 4 (5) 472-472; DOI:10.1158/2326-6066.CIR-16-0065

Back to top
PreviousNext
Cancer Immunology Research: 4 (5)
May 2016
Volume 4, Issue 5
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • Cancer Immunology at the Crossroads: Complementary Therapeutic Modalities
  • Cancer Immunology Miniatures
  • Research Articles
  • Correction
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Characterization of Murine Syngeneic Tumor Models
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement